IGM Biosciences (IGMS) plans to slash its workforce by 73% to preserve cash and assess strategic alternatives to maximize value for shareholders.
Developments of the imvotamab and IGM-2644 autoimmunity pipeline programs are being halted, the company said Thursday in a statement.
"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success," IGM Chief Executive Officer Mary Beth Harler said in the statement.
"Concurrent with discontinuation of the imvotamab program, IGM-2644 is also being terminated due to strategic considerations," Harler said.
The company said it had unaudited cash and investments of $183.8 million as of Dec. 31.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.